Clinical Trial: Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC

U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07750704) titled 'Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC' on Aug. 02.

Brief Summary: This investigator-initiated, open-label, prospective Phase II clinical trial, planned to take place across multiple centers in China. We design this trial to evaluate the safety and efficacy of lorlatinib plus sacituzumab tirumotecan based on peripheral blood ctDNA as first-line treatment for ALK fusion NSCLC.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: ALK Positive Non-small Cell Lung Cancer

Intervention: DRUG: Lorlatinib

lorlatinib 100 mg orally once da...